{
  "ticker": "C7A",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966722",
  "id": "02966722",
  "pages": 29,
  "price_sensitive": false,
  "date": "20250707",
  "time": "1407",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06lk0v8638h8s1.pdf",
  "summary": "### **Summary of Material Information \u2013 Clara Resources Australia Limited (General Meeting Notice - Capital Raisings & Share Issues)**  \n\n#### **Capital Raising & Share Issuances**  \n1. **Placement Tranche 1 (Ratification)**  \n   - **76.67M shares** issued at **$0.003/share** (total: **$230k**) on **20 June 2025**.  \n   - Requires ratification under ASX Listing Rule 7.4.  \n\n2. **Placement Tranche 2 (Approval)**  \n   - **113.33M shares** at **$0.003/share** (total: **$340k**) to unrelated investors.  \n   - **10M shares** to Director Alex Fitzgerald\u2019s nominee (related party, requires LR 10.11 approval).  \n\n3. **Director/Employee Shares in Lieu of Fees** (All at $0.003/share):  \n   - **18.4M shares** to MD Peter Westerhuis (unpaid salary).  \n   - **5.45M shares** to Chair Richard Willson (unpaid director fees).  \n   - **7.84M shares** to CFO Peter Harding-Smith (unpaid contractor fees).  \n\n4. **Lead Manager Options**  \n   - **35.58M options** to Peak Asset Management & Cerberus Advisory.  \n   - Strike: **$0.0075**, expiry: **31 May 2027**.  \n\n5. **Deferred Broker Options**  \n   - **9.27M options** to Foster Stockbroking.  \n   - Strike: **$0.012**, expiry: **31 December 2027**.  \n\n#### **Key Dates/Terms**  \n- **Meeting Date**: **5 August 2025** (Record date: **3 August 2025**).  \n- **Funds Use**: Ashford coking coal project & working capital.  \n- **Voting Exclusions**: Related parties excluded from voting on relevant resolutions.  \n\n#### **Impact**  \n- **Dilution**: Significant issuance (~246M new shares + options) at deep discount to market.  \n- **Liquidity**: Post-issue, ~4.6% of shares held by directors/associates (post-dilution).  \n\n**Note**: Routine corporate actions; focus on approval outcomes and dilution.",
  "usage": {
    "prompt_tokens": 17196,
    "completion_tokens": 491,
    "total_tokens": 17687,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T05:02:46.888907"
}